Premier Biomedical Receives Notice Of Allowance On Broad Base Patent Involving Innovative Extracorporeal Treatment Therapy – Premier Believes This May Lead To Cancer Cure

EL PASO, Texas--(BUSINESS WIRE)--Premier Biomedical, Inc. (OTCQB: BIEI) a biotech research public company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans, including innovative therapies for breast cancer as well as potential novel therapies for neurofibromatosis, atherosclerosis and muscular dystrophy, announced today they have obtained exclusive rights to the recently allowed U.S. patent application, “Sequential Extracorporeal Treatment of Bodily Fluids”, covering the basic technology underpinning Premier’s on-going research into new, innovative treatments for many of today’s most debilitating diseases.

Premier Biomedical, Inc. is developing a methodology for treating multiple diseases, such as cancer, which is completely different from the standard treatments now being utilized. The vast majority of presently known treatments directly inject possibly harmful agents into the body of a patient. This presents a very real risk of adverse side effects from the treatment.

Premier Biomedical, Inc. intends to develop its proprietary methodology in which the pathologies are eradicated by sequentially dialyzing the patient’s blood extracorporeally (outside the body). The method will utilize designer antibodies to physically remove the pathophysiologic basis of the disease. For example, in cancer treatment, there will be the physical attachment and removal of metastasizing cancer cells, proteins or molecules which are responsible for the development, progression and metastasis of the disease. This extracorporeal methodology has an enormous potential for dramatically decreasing any side effects in the treatment of ill patients. The estimated expenditures for cancer treatment in the U.S. in 2010 were approx. $124.5 Billion, and projected to rise to $158 - $175 Billion by 2020¹.

William A. Hartman, CEO and President of Premier Biomedical, stated that, “Between this sequential extracorporeal therapy patent just granted, and the previously granted patent Utilization of Stents for the Treatment of Blood Borne Carcinomas (US Patent 8,758,287: 6/24/14), I believe that we have a clear roadmap for potentially curing cancer, possibly at any stage, and even after extensive metastasis. These patents support our on-going experimentation and plans to present our stunning results to the American Association for Cancer Research (AACR) in December.” Mr. Hartman can be contacted via email at w.hartman@premierbiomedical.com or by phone at (PBI) MED-7033 / (724) 633-7033.

About Premier Biomedical, Inc.

Premier Biomedical, Inc. (OTCQB: BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). The company’s R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. The Company is a fully-reporting issuer whose common stock trades on the OTCQB marketplace maintained by OTC Markets Group, Inc. under the ticker symbol “BIEI.” http://www.premierbiomedical.com/. For more information please contact: William A. Hartman, President and CEO, Premier Biomedical Inc., at (724) 633-7033 or via email w.hartman@premierbiomedical.com

Safe Harbor Notice

Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.

¹ Cancer costs projected to reach at least $158 billion in 2020; Posted: January 12, 2011, http://www.cancer.gov/news-events/press-releases/2011/costcancer2020

Help employers find you! Check out all the jobs and post your resume.